

## Peer Review File

Article information: <https://dx.doi.org/10.21037/tcr-23-1547>

### Review Comments

#### Reviewer A

**Comment 1:** The case is of little significance. Several comparable reports have been published. I would therefore encourage the authors to report a case series of 3-5 cases and not a single case. This would add scientific value.

**Reply:** Our facility does not have that many cases, so this is a single case report.

**Changes in the text:** None

**Comment 2:** The issue in IVC thrombectomy is not the surgical approach. The question is not whether to perform robotic or open surgery. The issue in the current case is the morbidity of surgery, which increases with the extension of the thrombus.

**Reply:** We have modified our text as advised.

**Changes in the text:** Page9, line143-144

**Comment 3:** Comorbidity and age were also present after presurgical treatment. The focus of the manuscript on robotic surgery should be softened. The real question is whether to perform medical treatment to reduce surgical morbidity and not whether to use the robot.

Several important manuscripts are not cited, such as cumulative analyses of TKI based treatment (<https://doi.org/10.1111/bju.15966>) or NAXIVA.

**Reply:** We have modified our text as advised.

**Changes in the text:** Page10, line163-168; Page12-13, line227-229

#### Reviewer B

**Comment 4:** In this case report, preoperative pembrolizumab+axitinib therapy was administered with the aim of reducing the level of IVC tumor before performing radical nephrectomy. In the era of IO-drugs, such a treatment setting is anticipated to be quite common. Similar case reports already exist in abundance, and there are limitations in terms of novelty. The planning and execution of pre-surgical chemotherapy duration remain unclear, and there is no consensus on this matter, which may potentially result in missed opportunities for curative treatment due to adverse events or treatment resistance.

**Reply:** We have modified our text as advised.

**Changes in the text:** Page7 line99-100

**Comment 5:** A minor issue is the absence of information regarding whether a tumor biopsy was performed prior to surgery. These combination drugs are promising for the treatment of clear cell renal carcinoma.

**Reply:** We have modified our text as advised.

Changes in the text: Page6-7, line94-96

**Comment 6:** As for the surgical details, it is essential to include patient characteristics such as BMI and abdominal surgery history.

Reply: We have modified our text as advised.

Changes in the text: Page6, line89-90